Grade 1 Follicular Lymphoma

Oncology·MeSH: Lymphoma, Follicular

Prevalence

56.0 / 100K

Incidence

19.6 / 100K/yr

8 drugs in development·3 companies·2 clinical trials

Drug Pipeline by Phase

Phase 2(8)

Drug	Company
Bendamustine Hydrochloride	FATE THERAPEUTICS INC (FATE)
Obinutuzumab	FATE THERAPEUTICS INC (FATE)
Obinutuzumab	Merus N.V. (MRUS)
Umbralisib	Filana Therapeutics Inc. (FLNA)
Umbralisib	Merus N.V. (MRUS)
Umbralisib	FATE THERAPEUTICS INC (FATE)
Vincristine	FATE THERAPEUTICS INC (FATE)
Vincristine Sulfate	FATE THERAPEUTICS INC (FATE)

BioSniper tracks 8 drugs in development for Grade 1 Follicular Lymphoma across 3 companies.

There are 2 clinical trials targeting Grade 1 Follicular Lymphoma tracked by BioSniper.

The estimated prevalence of Grade 1 Follicular Lymphoma is approximately 56.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.